NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 45 filers reported holding NEUROCRINE BIOSCIENCES INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,195,521 | +2.6% | 1,546,000 | -4.2% | 0.02% | 0.0% |
| Q2 2022 | $2,139,249 | +99.8% | 1,614,000 | +98.3% | 0.02% | +157.1% |
| Q1 2022 | $1,070,922 | +0.9% | 814,000 | -3.6% | 0.01% | +16.7% |
| Q4 2021 | $1,061,002 | -53.7% | 844,000 | -51.2% | 0.01% | -57.1% |
| Q2 2021 | $2,292,849 | -57.0% | 1,729,000 | -55.2% | 0.01% | -76.3% |
| Q3 2020 | $5,337,000 | -39.5% | 3,859,000 | -27.1% | 0.06% | -43.3% |
| Q2 2020 | $8,822,000 | +51.8% | 5,293,000 | +16.7% | 0.10% | +62.5% |
| Q1 2020 | $5,811,000 | -8.9% | 4,536,000 | +9.1% | 0.06% | +30.6% |
| Q4 2019 | $6,376,000 | +5915.1% | 4,158,000 | +5300.0% | 0.05% | +4800.0% |
| Q3 2019 | $106,000 | -26.9% | 77,000 | -30.0% | 0.00% | 0.0% |
| Q2 2019 | $145,000 | -12.7% | 110,000 | -10.6% | 0.00% | 0.0% |
| Q1 2019 | $166,000 | -92.8% | 123,000 | -93.6% | 0.00% | -94.7% |
| Q4 2018 | $2,297,000 | -9.2% | 1,924,000 | 0.0% | 0.02% | +35.7% |
| Q1 2018 | $2,530,000 | – | 1,924,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SSI INVESTMENT MANAGEMENT LLC | 7,440,000 | $10,058,000 | 0.84% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,121,000 | $5,579,000 | 0.72% |
| Baker Brothers Advisors | 53,270,000 | $71,994,000 | 0.46% |
| LINDEN ADVISORS LP | 11,675,000 | $15,814,000 | 0.36% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 11,558,000 | $15,650,000 | 0.34% |
| AQR Arbitrage LLC | 20,000,000 | $27,077,000 | 0.34% |
| CSS LLC/IL | 3,455,000 | $4,675,000 | 0.28% |
| RWC Asset Management LLP | 4,000,000 | $5,396,000 | 0.25% |
| MACKAY SHIELDS LLC | 21,460,000 | $29,043,000 | 0.21% |
| Calamos Advisors LLC | 24,105,000 | $32,660,000 | 0.20% |